Madrigal Pharmaceuticals

MDGL

Market cap $11.5B

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.

CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, strengthening the company's leadership in shaping the next generation of MASH therapies and combination regimens. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inflammation in the liver.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Madrigal (MDGL). But which of these two companies is the best option for those looking for undervalued stocks?

The bull case wasn't helped by an analyst's recommendation downgrade. That pundit now feels the biotech's shares only rate a hold.

Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.

Madrigal Pharmaceuticals maintains a "Strong Buy" rating, driven by Rezdiffra's FDA approval for F2-F3 MASH and robust sales momentum. MDGL is expanding Rezdiffra's reach, targeting F4 compensated MASH cirrhosis with the pivotal phase 3 MAESTRO-NASH-OUTCOMES trial; data is expected in 2027. Two-year open-label data show Rezdiffra improves key biomarkers in hard-to-treat F4c MASH cirrhosis patients, supporting further development.

CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST.

Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.